Sitryx Therapeutics secures $39 million funding for disease-modifying therapeutics.
Sitryx Therapeutics, headquartered in Oxford, UK, is a biopharmaceutical company dedicated to developing disease-modifying therapeutics for chronic autoimmune and inflammatory diseases by regulating cell metabolism. Recently, the company secured $39 million in funding, with new investor Oxford Science Enterprises (OSE) joining existing healthcare investors SV Health Investors, Eli Lilly & Company (Lilly), Sofinnova Partners, Longwood Fund, and GSK. Sanne de Jongh, Partner at Oxford Science Enterprises, has joined Sitryx' Board. The funds raised will be utilized to advance the company's immunometabolism-targeting therapies into clinical development.
Founded in 2018 by renowned researchers in immunology and metabolism such as Houman Ashrafian, Luke O'Neill, Jonathan Powell, Jeff Rathmell, Michael Rosenblum, and Paul Peter Tak, and led by Chief Executive Officer Neil Weir, Sitryx aims to create a diverse pipeline of proprietary therapies by identifying innovative targeted approaches based on the impact of metabolic changes on immune cell function.
Sitryx initially received seed funding from SV Health Investors when it was established in 2018, followed by a $30 million Series A funding.
In 2020, the company entered into an exclusive global licensing and research collaboration agreement with Eli Lilly and Company, resulting in Lilly also becoming an investor in Sitryx.
They've invested in Sitryx Therapeutics
Get to know these Healthtech investors
| Investor | Sector | Stage | Activity | Team | Connect |
|---|---|---|---|---|---|
 Oxford Science Enterprises | 29 investments investments | 1 contact contact | |||
 SV Health Investors | 6 investments investments | 6 contacts contacts | |||
 Eli Lilly & Company | 3 investments investments | 1 contact contact | |||
 Sofinnova Partners | 12 investments investments | 25 contacts contacts | |||
 Longwood Fund | 1 investment investment | 8 contacts contacts |
Click here for a full list of 7,526+ startup investors in the UK